GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Arecor Therapeutics AREC.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

77.50p

0.00%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Arecor Therapeutics — daily AREC

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Arecor Therapeutics on TradingView ↗
Market value
£29.3m
Last close × shares
Volume
8k
Shares, 9 Nov 2026
Price to earnings
3139.9

About Arecor Therapeutics

Its shares trade on LSE under the ticker AREC.L. It has been listed since 3 June 2021. In the fiscal year to 31 December 2025, it reported revenue of £1.7m and net income of £664,000. At that date it held total assets of £8.1m and shareholders' equity of £6.5m.

Arecor Therapeutics Plc is a biopharmaceutical company that targets improving patient care by bringing medicines to market through the enhancement of existing therapeutic products. The company is headquartered in Saffron Walden, Essex. The company went IPO on 2021-06-03. The Company, through its formulation technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver formulations of their therapeutic products. Its clinical development programs include AT247-Ultra-Rapid Acting Insulin and AT278-Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. AT278 is a concentrated formulation of rapid acting insulin that is designed to accelerate the absorption of insulin post injection, even when delivered at a high concentration, and hence via a lower injection volume. The company also has Tetris Pharma portfolio.

Figures and description from our data supplier, not checked against the company's own report.

More about Arecor Therapeutics →

Latest on Arecor Therapeutics

Our reporting

We have not reported on Arecor Therapeutics yet.

Next results

27 Apr 2027

Due on 27 Apr 2027.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Arecor Therapeutics's ticker?

Arecor Therapeutics trades as AREC.L on LSE, under ISIN GB00BMWLM973.

What was Arecor Therapeutics's last closing price?

77.50p on 9 Nov 2026. The figure is in GBp and is never converted.

When does Arecor Therapeutics next report results?

Results are expected on 27 Apr 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.